Will new lawsuit delay commercialization of AquaBounty’s GM salmon?

AquaBounty Lawsuit just another attempt to delay commercialization of GE salmon strict xxl
Image: Food Navigator.

AquaBounty Technologies, which hopes to become the first company to introduce a genetically engineered animal to the human food supply, says a legal challenge to Environment Canada’s decision to approve its technology is just the latest attempt by its opponents to delay the commercialization process.

The company’s AquAdvantage salmon contains a growth hormone gene that allows the salmon to mature twice as fast as conventional salmon. In November 2013, Environment Canada concluded that the GE salmon was not harmful to human health or the environment. The application for a judicial review, filed by two environmental groups, alleges that the Canadian government failed to conduct a full risk assessment before giving AquaBounty the thumbs up.

“This has been the most transparent and rigorous process ever conducted,” said AquaBounty CEO Ron Stotish. “Multiple regulatory agencies in two countries have concluded multiple times that our salmon is environmentally safe. They are backed up by the consensus of the credible scientific community.”

“This law suit is nothing more than an attempt to continue to delay a process that has already taken 20 years,” he added.

Read the full, original article: AquaBounty: Lawsuit just another attempt to delay commercialization of GE salmon

Additional Resources:

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

ChatGPT-Image-May-7-2026-12_16_37-PM-2
Viewpoint: Are cancer rates ‘skyrocketing’ as RFK, Jr. and MAHA claims? The evidence says mostly the opposite
Screenshot-2026-04-22-at-10.46.29-AM
Viewpoint: How to counter science disinformation? Science journalist offers 12 practical tips
ChatGPT-Image-May-12-2026-08_39_41-PM
GLP podcast: Big Pharma, Big Ag, Big Food—health harming industries or life-saving innovators?
png-pill-omega-Supp-fish-oil
Millions take omega-3 fish oil for brain health. New research suggests it may do the opposite.
Screenshot-2026-04-23-at-11.00.36-AM
Regulators' dilemma: Thalidomide, Metformin, and the cost of getting drug approvals wrong
Screenshot-2026-02-20-at-10.48.04-AM
Deepfakes raise profound ethical questions in science
Picture1-1
Cooling the planet with balloons: Could a geoengineering gamble slow global warming?
Picture1-5
Science Disinformation Gap: The transatlantic battle over social media and censorship
Screenshot-2026-05-08-at-3.40.33-PM
Seeds of power: China turns to genetic engineering to become global superpower
Screenshot-2026-04-13-at-1.39.26-PM
Viewpoint: ‘Safer for children?’ Stonyfield yogurt under fire for deceptive organic marketing
ChatGPT-Image-May-12-2026-01_41_42-PM
Viewpoint: ‘Measles is a canary in the healthcare coal mine’: Challenging RFK, Jr.’s scare campaign
ChatGPT-Image-May-13-2026-11_56_08-AM
After slashing global health aid by $19 Billion, Trump moves to tap $2.1 billion more—to cover shutdown costs
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.